Immunocore Holdings plc (NASDAQ:IMCR) Short Interest Update

Immunocore Holdings plc (NASDAQ:IMCR) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 6,680,000 shares, an increase of 29.2% from the May 15th total of 5,170,000 shares. Based on an average daily volume of 699,900 shares, the days-to-cover ratio is currently 9.5 days. Currently, 13.8% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IMCR. Oppenheimer reiterated an “outperform” rating and set a $87.00 target price (up previously from $85.00) on shares of Immunocore in a research note on Thursday, February 29th. JPMorgan Chase & Co. increased their target price on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Guggenheim reiterated a “buy” rating and set a $92.00 target price on shares of Immunocore in a research note on Tuesday, April 23rd. Needham & Company LLC reiterated a “buy” rating and set a $81.00 target price on shares of Immunocore in a research note on Monday, June 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, June 5th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.85.

Immunocore Trading Down 3.1 %

NASDAQ:IMCR traded down $1.23 on Friday, reaching $38.46. The stock had a trading volume of 684,351 shares, compared to its average volume of 1,345,820. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -31.52 and a beta of 0.83. Immunocore has a 12-month low of $38.21 and a 12-month high of $76.98. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94. The firm’s fifty day moving average is $52.53 and its two-hundred day moving average is $61.48.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The firm had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The firm’s revenue was up 27.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. Equities analysts expect that Immunocore will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Bellevue Group AG boosted its holdings in Immunocore by 4,817.1% in the fourth quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after acquiring an additional 956,204 shares during the last quarter. Braidwell LP raised its holdings in shares of Immunocore by 93.8% in the 3rd quarter. Braidwell LP now owns 906,973 shares of the company’s stock worth $47,072,000 after purchasing an additional 438,946 shares during the period. Wellington Management Group LLP lifted its stake in shares of Immunocore by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after purchasing an additional 399,201 shares in the last quarter. First Turn Management LLC purchased a new stake in shares of Immunocore during the 4th quarter worth about $23,439,000. Finally, Polar Capital Holdings Plc increased its position in Immunocore by 490.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 250,000 shares of the company’s stock worth $12,975,000 after purchasing an additional 207,664 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.